2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.
While there are some broad frameworks in place for decision-making, Tripathy says, many patients do not fit easily into those frameworks. In the first-line, patients who have not been treated with trastuzumab (or were treated with trastuzumab over one year ago) should receive a combination of trastuzumab, pertuzumab, and docetaxel or another taxane. The question then remains as to how this group should be treated next, Tripathy says.
It is known that T-DM1 is superior to capecitabine and lapatinib, but again, questions remain regarding what should be done when a patient progresses in a short period of time. Tripathy says oncologists can treat based on phase II results, but there is no way to definitively know what is best for a given situation.